XORTX Therapeutics Inc. (“XORTX” or the “Company“) (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce positive topline results from the XRX-OXY-101 – Bridging Pharmacokinetics Clinical Trial (the “Study“) characterizing the pharmacokinetics of the Company’s proprietary formulation of oral oxypurinol, XORLOTM. Results from the Study showed that XORLOTM was well tolerated across the various dosing regimens. No safety issues were identified in any of the four parts of the Study on the 88 subjects who received drug. Results from the four parts of the Study showed (i) a substantial increase in the bioavailability of oxypurinol with the XORLOTM formulation platform; (ii) increased dose proportionality compared to non-formulated oxypurinol; (iii) a multiple dosing regimen that achieved therapeutic target values; and (iv) confirmation of the innovations claimed in the recently granted US and EU patents regarding the Company’s unique proprietary formulations of oxypurinol.
Lady Gaga Went Bankrupt Before She Grew Her Fortune To $150M — She Still Doesn’t ‘Care About The Money’
Stefani Germanotta, better known as Lady Gaga, has amassed a net worth of $150 million, per Forbes, but her journey to riches was a far cry from a straight shot.
